365 Days of Progress In Molecular and Cellular Oncology

11.1K

views

23

authors

4

articles

Editors

2

Luisa Lanfrancone

European Institute of Oncology (IEO)

University of New South Wales

Impact

About

“365 Days of Progress” is part of a wider series of Research Topics across Frontiers in Oncology, hosted by our Specialty Chief Editors, showcasing popular articles from 2021 igniting interest in the field.

This Research Topic aims to highlight the work featured and spark further discussion. The Molecular and Cellular Oncology field is continuously evolving, therefore we are seeking to understand developments and perspectives on articles that have attracted attention throughout the year.

We welcome Opinions, Perspectives, and Mini-Review article types to facilitate this discussion. We also welcome updated original data following the research featured in this collection. Please note only papers that are relevant and add a significant contribution to the discussion articles will be considered.

The chosen manuscripts are :

- Unbiased Phenotype-Based Screen Identifies Therapeutic Agents Selective for Metastatic Prostate Cancer
- The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer
- MYCN Function in Neuroblastoma Development
- New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil
- Fibroblast Activation Protein-a as a Target in the Bench-to-Bedside Diagnosis and Treatment of Tumors: A Narrative Review
- Targeting MYCN in Pediatric and Adult Cancers
- Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature
- From Good to Bad: The Opposing Effects of PTHrP on Tumor Growth, Dormancy, and Metastasis Throughout Cancer Progression
- The Prolactin Inducible Protein Modulates Antitumor Immune Responses and Metastasis in a Mouse Model of Triple Negative Breast Cancer
- Propranolol Sensitizes Vascular Sarcoma Cells to Doxorubicin by Altering Lysosomal Drug Sequestration and Drug Efflux

Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.

“365 Days of Progress” is part of a wider series of Research Topics across Frontiers in Oncology, hosted by our Specialty Chief Editors, showcasing popular articles from 2021 igniting interest in the field.

This Research Topic aims to highlight the work featured and spark further discussion. The Molecular and Cellular Oncology field is continuously evolving, therefore we are seeking to understand developments and perspectives on articles that have attracted attention throughout the year.

We welcome Opinions, Perspectives, and Mini-Review article types to facilitate this discussion. We also welcome updated original data following the research featured in this collection. Please note only papers that are relevant and add a significant contribution to the discussion articles will be considered.

The chosen manuscripts are :

- Unbiased Phenotype-Based Screen Identifies Therapeutic Agents Selective for Metastatic Prostate Cancer
- The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer
- MYCN Function in Neuroblastoma Development
- New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil
- Fibroblast Activation Protein-a as a Target in the Bench-to-Bedside Diagnosis and Treatment of Tumors: A Narrative Review
- Targeting MYCN in Pediatric and Adult Cancers
- Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature
- From Good to Bad: The Opposing Effects of PTHrP on Tumor Growth, Dormancy, and Metastasis Throughout Cancer Progression
- The Prolactin Inducible Protein Modulates Antitumor Immune Responses and Metastasis in a Mouse Model of Triple Negative Breast Cancer
- Propranolol Sensitizes Vascular Sarcoma Cells to Doxorubicin by Altering Lysosomal Drug Sequestration and Drug Efflux

Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.

Share

Editors

Luisa Lanfrancone

European Institute of Oncology (IEO)

University of New South Wales

Impact

11,090 Total views

6,731 Article views

4,098 Article downloads

261 Topic views

Published In

Journal Thumbnail

Frontiers in Oncology

Molecular and Cellular Oncology

Journal Thumbnail

Frontiers in Cell and Developmental Biology

Molecular and Cellular Oncology

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic